Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 5/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 16/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497446 | 1.00 | CTSB (0.47) | CTSBCTSSCTSKKDM4EMEN1 | |
| SCHEMBL29076290 | 0.88 | CTSK (0.52) | CTSBCTSSCTSK | |
| SCHEMBL30497445 | 0.88 | CTSK (0.52) | CTSBCTSSCTSK | |
| SCHEMBL29076287 | 0.88 | CTSK (0.52) | CTSBCTSSCTSK | |
| SCHEMBL29076337 | 0.84 | CTSB (0.41) | CTSBCTSSCTSK | |
| SCHEMBL29076335 | 0.84 | CTSB (0.41) | CTSBCTSSCTSK | |
| SCHEMBL30497450 | 0.84 | CTSB (0.41) | CTSBCTSSCTSK | |
| SCHEMBL30497451 | 0.84 | CTSB (0.41) | CTSBCTSSCTSK | |
| SCHEMBL30497449 | 0.82 | CTSK (0.51) | CTSBCTSSCTSK | |
| SCHEMBL29076137 | 0.81 | CTSK (0.65) | CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145576-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | claimed |
| EP-4467544-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2024-11-27 | — | — | EP | claimed |
| WO-2023138695-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东新时代药业有限公司 | 2023-07-27 | — | — | WO | claimed |
| US-20250145576-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4467544-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023138695-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 山东新时代药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145576-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CTSF, CTSK, CTSZ | CTSB 9/4885CTSS 4/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.